Weider Q3 financials
This article was originally published in The Tan Sheet
Executive Summary
Increased private label sales of $12.7 mil. were offset by a 16.7% decrease in Move Free revenue,execs say during April 8 analysts call. Third quarter net sales fell 14.3% to $64.1 mil., while net income dipped 35.3% from $1.2 mil. in Q3 2002 to $808,000 this year. Salt Lake City-based firm plans to launch nine "new leading-edge technology SKUs under the Weider brand by the end of the fourth quarter." Three products to be introduced under the Body Shaper sub-brand include Diet & Energy, Metabolizer and CLA Complete...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.